StockNews.AI
IMUX
StockNews.AI
82 days

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

1. Immunic announces public offering of warrants to purchase common stock at $0.7499.

2m saved
Insight
Article

FAQ

Why Bearish?

Public offerings often dilute existing shares, impacting short-term share price. Past instances show dilution can lead to immediate price drops for biotech firms.

How important is it?

The announcement directly affects share dilution and investor sentiment towards IMUX's financial health.

Why Short Term?

The effect of public offerings is typically felt quickly, influencing stock price in the near term.

Related Companies

AMGNABBVJNJ
NEW YORK , May 29, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "Pre-Funded Warrants"), (ii) series A warrants to purchase shares of common stock (or pre-funded warrants) (the "Series A Warrants"), and (iii) series B warrants to purchase shares of common stock (or pre-funded warrants) (the "Series B Warrants"). The combined public offering price of one Pre-Funded Warrant, one Series A Warrant, and one Series B Warrant, which are being sold together but are immediately seperable, is $0.7499.

Related News